AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16648085
Drug: Standardized treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatments
Trial: 9176531
Drug: Intrapleural streptokinase,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural streptokinase, 250,000 i.u. daily for three days
Trial: 1545974
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution intra‐alveolar dressings
Trial: 16353046
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) with hydrochlorothiazide (25 mg)
Trial: 16353046
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg) with hydrochlorothiazide (25 mg)
Trial: 10924001
Drug: d,l‐fenfluramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐fenfluramine (100 mg orally)
Trial: 1387512
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) 40 micrograms via metered dose inhaler (MDI)
Trial: 1387512
Drug: Fenoterol (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (not specified dosage)
Trial: 6516414
Drug: Theophylline administered
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline administered in aqueous solution
Trial: 6516414
Drug: Theophylline oral
RxNorm normalized name: theophylline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline oral preparations
Trial: 6516414
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Theophylline
Trial: 27137756
Drug: sufentanil 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 2.5 μg
Trial: 27137756
Drug: sufentanil 5
RxNorm normalized name: SUFentanil 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 5 μg
Trial: 27137756
Drug: fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 25 μg
Trial: 24835719
Drug: Formulary applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulary applications for new drugs or new indications (95 applications)
Trial: 24835719
Drug: Applications reviewed
RxNorm normalized name: Renewal
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applications reviewed by statewide medicines advisory committee or hospital pharmacist (45 applications)
Trial: 18049317
Drug: ADHD medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD medication use
Trial: 11834115
Drug: Creatine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (0.3 g x kg(‐1) x d(‐1)) with 1-minute recovery interval
Trial: 11834115
Drug: Creatine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (0.3 g x kg(‐1) x d(‐1)) with 3-minute recovery interval
Trial: 7743615
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (rTPA)
Trial: 30605708
Drug: Add-on 10Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on 10Hz rTMS treatment (20 times)
Trial: 23759326
Drug: Screening every
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening every 4 years with PSA level cut-off ≥ 3.0 ng/ml as biopsy indication (S-arm)
Trial: 21342773
Drug: Adenosine pretreatment
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine pretreatment (2.45 mg kg⁻¹ over 10 min)
Trial: 18539916
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (gliclazide modified release plus other drugs)
Trial: 12768462
Drug: Acamprosate (1332
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1332 mg daily)
Trial: 8898507
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 25 micrograms/hr
Trial: 8898507
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 50 micrograms/hr
Trial: 1725280
Drug: PPF (DDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPF (DDP 100 mg/m2 + pingyangmycin + 5‐FU) regimen plus radiotherapy
Trial: 27854209
Drug: Aceneuramic acid
RxNorm normalized name: ACENEURAMIC ACID
DrugBank: Aceneuramic acid (DB11797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceneuramic acid extended-release (Ace-ER) 6g/day
Trial: 27854209
Drug: Aceneuramic acid
RxNorm normalized name: ACENEURAMIC ACID
DrugBank: Aceneuramic acid (DB11797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceneuramic acid extended-release (Ace-ER)
Trial: 24559216
Drug: Intensive combination
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive combination treatment strategies (ICTS) for early RA
Trial: 24559216
Drug: Conventional disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional disease-modifying anti-rheumatic drugs (DMARDs) plus step-down glucocorticoids (GCs)
Trial: 15778268
Drug: Neostigmine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.04 mg kg(‐1) and glycopyrrolate 0.01 mg kg(‐1)
Trial: 12501883
Drug: Oral gemifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gemifloxacin 320 mg once daily (7-14 days)
Trial: 12501883
Drug: IV ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ceftriaxone 2 g once daily (1-7 days) followed by oral cefuroxime 500 mg twice daily (1-13 days)
Trial: 10362176
Drug: Birth weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth weight of at least 4000 g
Trial: 2183645
Drug: Methylprednisolone pulse
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulse therapy (MPPT) - 1 g intravenously
Trial: 29143428
Drug: Alfacalcidol 0.5
RxNorm normalized name: alfacalcidol 0.5 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.5 μg/day + Calcium 500 mg/day
Trial: 29143428
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Calcium 500 mg/day
Trial: 16911730
Drug: Pre-treatment attentional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment attentional bias
Trial: 10588819
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (0.3 mg)
Trial: 8738728
Drug: Isosorbide‐5‐mononitrate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (40 mg, orally; n = 12)
Trial: 1820892
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 2 mg idaverine
Trial: 1820892
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1 mg idaverine
Trial: 1820892
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 2 mg idaverine
Trial: 1820892
Drug: Idaverine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idaverine (all doses)
Trial: 6357018
Drug: Intermittent positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent positive pressure breathing (IPPB) therapy
Trial: 6357018
Drug: Compressor nebulizer
RxNorm normalized name: Compressor Nebulizer NE-C25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compressor nebulizer therapy
Trial: 27157843
Drug: Topical bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bimatoprost ocular insert
Trial: 27157843
Drug: Timolol (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (0.5% solution) eye drops
Trial: 23808510
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (lignocaine)
Trial: 14967869
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (CHO) 1.0 g x kg body mass(-1)
Trial: 11069375
Drug: Adjuvant mitozantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant mitozantrone chemotherapy
Trial: 8686962
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 5‐ISMN once daily for one week followed by 60 mg 5‐ISMN once daily for one week
Trial: 8686962
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg 5‐ISMN once daily for two weeks
Trial: 8686962
Drug: Starting on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting on a low dosage
Trial: 31200819
Drug: Chemotherapy (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (first line)
Trial: 22652402
Drug: ASO3-adjuvanted H1N1pdm09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given concurrently
Trial: 22652402
Drug: ASO3-adjuvanted H1N1pdm09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given sequentially (21 days later)
Trial: 22652402
Drug: H1N1pdm09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1N1pdm09 vaccine alone
Trial: 18586189
Drug: Hyaluronidase injection
RxNorm normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase injection (n = 71)
Trial: 18586189
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (control group, n = 68)
Trial: 11906779
Drug: Separate injection
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injection vaccination (DTPw-HB and Hib)
Trial: 10422951
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg for induction followed by propofol 75‐150 microg x kg(‐1) x min(‐1) for maintenance
Trial: 10422951
Drug: Sevoflurane in
RxNorm normalized name: sevoflurane Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane in combination with N2O 67% in oxygen for induction and maintenance
Trial: 11198784
Drug: Fibernat (dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibernat (dietary fiber preparation)
Trial: 9107166
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg sublingual nitroglycerin administration
Trial: 8473716
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg/day
Trial: 8473716
Drug: Nefazodone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 400 mg/day
Trial: 8473716
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active compounds (Nefazodone and Imipramine)
Trial: 8473716
Drug: Imipramine 150
RxNorm normalized name: imipramine pamoate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 150 mg/day with alcohol
Trial: 8473716
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg/day with alcohol
Trial: 28938434
Drug: Insulin clamp
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin clamp studies
Trial: 31911348
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of the opioid receptor antagonist naltrexone
Trial: 26115878
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic plus exercise training
Trial: 26115878
Drug: AT1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1 receptor antagonist plus exercise training
Trial: 21744082
Drug: L-BLP25 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BLP25 plus BSC (stage IIIB loco-regional subgroup)
Trial: 9227540
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg body weight of 0.5 M racemic sodium lactate
Trial: 8435738
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor training programme (5 sessions, weekly, supervised by physiotherapists)
Trial: 2956873
Drug: Enoximone 50
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily for 4 weeks
Trial: 2956873
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given 3 times daily for 4 weeks
Trial: 2956873
Drug: Enoximone 50
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 50 mg and 100 mg, given 3 times daily
Trial: 2956873
Drug: Enoximone 150
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 150 mg, given 3 times daily
Trial: 2956873
Drug: Enoximone 50
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily
Trial: 30285645
Drug: Home-based physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physiotherapy (60 min, twice a week for 12 months)
Trial: 24033362
Drug: Control (Amalgam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Amalgam treatment)
Trial: 24033362
Drug: Greater treatment
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater treatment levels
Trial: 23168823
Drug: Citicoline (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (2000 mg daily for 90 days)
Trial: 15919846
Drug: TM-CD care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM-CD care (n = 329) including AUC elements plus 'stage of change' assessments, mailed workbooks, and monthly calls
Trial: 15919846
Drug: Augmented usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented usual care (AUC) (n = 336) including dietary and exercise advice, prescriptions, and dietary recalls
Trial: 15016225
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (no needle mounted)
Trial: 6542835
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (4.0 mmol h‐1 kg‐1 b. wht.)
Trial: 25496674
Drug: Topical lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lignocaine (7 puffs of 10% aerosol)
Trial: 25496674
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (1.5 mg/kg)
Trial: 25496674
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (5 ml of 0.9% saline)
Trial: 11865969
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (110, 220, 330, or 440 microg bid)
Trial: 10036950
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid + Amoxicillin 500 mg qid + Clarithromycin 400 mg bid (OAC)
Trial: 10036950
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid + Clarithromycin 400 mg bid (OC)
Trial: 2183719
Drug: Cefixime (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (800 mg oral dose)
Trial: 2183719
Drug: Amoxicillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (3 g) plus Probenecid (1 g)
Trial: 6601746
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Trial: 6601746
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg . kg‐1 lidoflazine intravenously before cardiopulmonary bypass (CPB)
Trial: 22055480
Drug: Daily multivitamin‐mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin‐mineral supplement
Trial: 10340839
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for isolated systolic hypertension; specific intervention details not provided.
Trial: 11324827
Drug: reverse transcriptase
RxNorm normalized name: Reverse transcriptase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reverse transcriptase inhibitors (zidovudine or didanosine monotherapy or alternating zidovudine and didanosine)
Trial: 7153153
Drug: Atropine 0.25
RxNorm normalized name: atropine 0.25 mg/0.3 mL intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.25 mg
Trial: 7153153
Drug: Atropine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 3.0 mg
Trial: 7153153
Drug: Atropine 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 6.0 mg
Trial: 30238444
Drug: Deferred endovenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred endovenous ablation of superficial venous reflux, with compression therapy alone
Trial: 24503784
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg once daily for ≈4 weeks)
Trial: 24503784
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral hypoglycemic agents)
Trial: 17575561
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Tramadol Contramid OAD tablet
Trial: 17575561
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Tramadol Contramid OAD tablet
Trial: 17575561
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Tramadol Contramid OAD tablet
Trial: 15694088
Drug: Intramuscular 15‐methyl‐prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 15‐methyl‐prostaglandin F2alpha (125 microg)
Trial: 10532693
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment with high doses of lovastatin (40-80 mg/day)
Trial: 10532693
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment with low doses of lovastatin (2.5-5 mg/day)
Trial: 7766739
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 4 weeks
Trial: 7766739
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg after 8 weeks
Trial: 7766739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg after 8 weeks
Trial: 7766739
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg after 2 weeks for patients with ulcer pain
Trial: 7766739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg after 2 weeks for patients with ulcer pain
Trial: 7766739
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg after 4 weeks for patients with ulcer pain
Trial: 7766739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg after 4 weeks for patients with ulcer pain
Trial: 31289056
Drug: Positive Adjustment
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Adjustment Coping Intervention (PACI) - daily text messages with positive-adjustment coping attitudes
Trial: 31289056
Drug: Cognitive distractions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive distractions - daily text messages with cognitive distractions
Trial: 22218098
Drug: Active blood
RxNorm normalized name: Accu-Chek Active Blood Glucose Meter Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active blood pressure lowering treatment (indapamide SR 1.5 mg plus perindopril 2-4 mg if required)
Trial: 16869334
Drug: Pharmacological comfort
RxNorm normalized name: Comfort Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological comfort treatments
Trial: 16869334
Drug: Nonpharmacological comfort
RxNorm normalized name: Comfort Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological comfort treatments
Trial: 10636264
Drug: Dipyridamole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (15 mg in 30 min, stopped 5 min before testing)